LCKLSL hydrochloride
Based on 8 publication(s) in Google Scholar
LCKLSL hydrochloride is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL hydrochloride potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL hydrochloride also inhibits the generation of plasmin and has anti-angiogenic roles.
For research use only. We do not sell to patients.
- Purity: 98.05%
- Formula: C30H58ClN7O8S
- Molecular Weight:712.34
-
Storage:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Cytoskeleton Compound Library
HY-L060
-
Peptide Library
HY-L105
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Peptide Compound Library
HY-L105S
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) LCKLSL hydrochloride
More- J Extracell Vesicles. 2024 Apr;13(4):e12425. [Abstract]
- J Immunother Cancer. 2025 Jun 26;13(6):e011716. [Abstract]
- Cell Commun Signal. 2024 Dec 21;22(1):616. [Abstract]
- Biomed Pharmacother. 2023 Mar:159:114173. [Abstract]
- Biochem Pharmacol. 2025 Sep 6;242(Pt 2):117308. [Abstract]
- Inflamm Res. 2022 Sep;71(9):1067-1078. [Abstract]
- iScience. 2025 Apr 2;28(5):112302. [Abstract]
- J Neurochem. 2022 Mar;160(6):662-674. [Abstract]
Customer Validation & Images
-
WB
Biological Activity
Annexin A2 (AnxA2)[1]
In human retinal microvascular endothelial cells (RMVECs), treatment with LCKLSL (0-2 mg) inhibits the generation of plasmin and suppresses the VEGF-induced activity of tPA under hypoxic conditions[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Molecular Weight 712.34
-
Formula C30H58ClN7O8S
-
Color White to off-white
-
Sequence
Leu-Cys-Lys-Leu-Ser-Leu
-
Sequence Shortening
LCKLSL
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
J Extracell Vesicles
2024 Apr;13(4):e12425. PMID: 38594791 -
J Immunother Cancer
Targeting Annexin A2 to reactivate tumor-associated antigens presentation and relieve immune tolerance in liver cancer. [Abstract]2025 Jun 26;13(6):e011716. PMID: 40571481 -
Cell Commun Signal
Exosomal ANXA2 facilitates ovarian cancer peritoneal metastasis by activating peritoneal mesothelial cells through binding with TLR2. [Abstract]2024 Dec 21;22(1):616. PMID: 39709496 -
Biomed Pharmacother
Isoliquiritigenin alleviates the development of alcoholic liver fibrosis by inhibiting ANXA2. [Abstract]2023 Mar:159:114173. PMID: 36680814
LCKLSL hydrochloride purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 Mar:159:114173. [Abstract]
LCKLSL (5 μM) intervention significantly inhibits ANXA2 protein expression levels when compare to the alcohol group, in activated HSC-T6 cells.
-
Biochem Pharmacol
Isoliquiritigenin inhibits the activation of the ANXA2/STAT3 pathway by down-regulating TAGLN2, thereby alleviating alcoholic fatty liver. [Abstract]2025 Sep 6;242(Pt 2):117308. PMID: 40921221 -
Inflamm Res
Inhibition of ANXA2 regulated by SRF attenuates the development of severe acute pancreatitis by inhibiting the NF-κB signaling pathway. [Abstract]2022 Sep;71(9):1067-1078. PMID: 35900381 -
iScience
Humanized mouse model reveals T cell ANXA2 as a potential therapeutic target in ischemic stroke. [Abstract]2025 Apr 2;28(5):112302. PMID: 40641552 -
J Neurochem
Activation of Annexin A2 signaling at the blood-brain barrier in a mouse model of multiple sclerosis. [Abstract]2022 Mar;160(6):662-674. PMID: 35064931
Solvent & Solubility
H2O : 50 mg/mL (70.19 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.51 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.51 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 8.33 mg/mL (11.69 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 1.4038 mL | 7.0191 mL | 14.0382 mL | 35.0956 mL |
| 5 mM | 0.2808 mL | 1.4038 mL | 2.8076 mL | 7.0191 mL | |
| 10 mM | 0.1404 mL | 0.7019 mL | 1.4038 mL | 3.5096 mL | |
| 15 mM | 0.0936 mL | 0.4679 mL | 0.9359 mL | 2.3397 mL | |
| 20 mM | 0.0702 mL | 0.3510 mL | 0.7019 mL | 1.7548 mL | |
| 25 mM | 0.0562 mL | 0.2808 mL | 0.5615 mL | 1.4038 mL | |
| 30 mM | 0.0468 mL | 0.2340 mL | 0.4679 mL | 1.1699 mL | |
| 40 mM | 0.0351 mL | 0.1755 mL | 0.3510 mL | 0.8774 mL | |
| 50 mM | 0.0281 mL | 0.1404 mL | 0.2808 mL | 0.7019 mL | |
| 60 mM | 0.0234 mL | 0.1170 mL | 0.2340 mL | 0.5849 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
LCKLSL hydrochloride Related Classifications
HY-P2333A Related Classifications
Powered by Bioz